IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
about
Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusSCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobankingType I interferon blockade in systemic lupus erythematosus: where do we stand?IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalinThe proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusLymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus.Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference?Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosusBaseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective studyBiomarkers in systemic lupus erythematosus: challenges and prospects for the future.SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.Sialoadhesin deficiency does not influence the severity of lupus nephritis in New Zealand black x New Zealand white F1 mice.Promising biomarkers for systemic lupus erythematosus.Targeting interferons in systemic lupus erythematosus: current and future prospects.Siglec-1 and -2 as potential biomarkers in autoimmune disease.Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review.Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus.Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study.Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint.Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.Tailoring Immune Responses toward Autoimmunity: Transcriptional Regulators That Drive the Creation and Collusion of Autoreactive Lymphocytes.Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
P2860
Q26782454-30DAED27-1BAF-46C5-B311-FCB8AC4F631EQ26853573-3B1DC598-1B52-4492-AEE1-9883B8510B18Q26865441-C8BD367C-9869-4CAF-86A8-E746FEC93E98Q33801351-2311157E-EECA-41C4-A1E9-DFCFB784B2FBQ33992328-E97A402E-87FD-4B0A-B508-97F1A665774CQ34464260-A9EC9A2A-1BE8-4E32-8823-0A1B39AD70F7Q34535634-A4C09D68-6594-4311-9D4C-7D06B50AEDE3Q34583337-C40BA484-D3CF-4AC8-9021-8CA38EBC29D3Q35082621-8ADFC3FA-4A72-4BBF-9F37-DC7956CF96C6Q36634362-F0016644-85E0-41B8-8C06-E65B8546A108Q36825365-30CEC83B-7AC3-4417-BE69-BAE592A7DCAFQ37058781-CCC82FE2-F7D6-4D28-9F5C-64CF359625A8Q37587370-2FA403ED-A8A1-424D-8C3A-7497F5F813C5Q37690188-646610BF-9EAA-4FF2-AC38-67AE6C9BCA32Q38149960-260DDAA8-05A4-42B3-AFD3-6E62A75D9CA1Q38458846-AAD22240-F671-4EDC-AC0B-622AF7363A7FQ38692196-64F349EA-74F7-4D98-976C-58C65E2C309DQ38867891-1A800B8F-B148-4C55-B296-3F4856746B4CQ39130536-9F97FC10-B190-48B8-9F88-A80DAAFB9369Q40072169-519355C6-E973-46B6-8369-D695609FCC65Q42634173-EBD884EE-A45A-44C4-9AF8-39DE417B64CBQ47267579-86028488-3D1E-4FED-A86B-2088E607C93FQ47875729-4410D7AB-77BD-40BD-AFBF-E1B2E475C93AQ48207773-415B451E-E6AF-472A-BC63-9E0D285697C0Q51724948-7B6C0A42-FE9C-4F9A-8A7A-56E4BE7B14FBQ55030447-DA22C2D7-D670-413C-B96E-4DC572649724Q58793379-E5B53CA6-0E59-4E79-976B-A1C02E982E50
P2860
IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
IFNα and its response proteins ...... systemic lupus erythematosus.
@en
IFNα and its response proteins ...... systemic lupus erythematosus.
@nl
type
label
IFNα and its response proteins ...... systemic lupus erythematosus.
@en
IFNα and its response proteins ...... systemic lupus erythematosus.
@nl
prefLabel
IFNα and its response proteins ...... systemic lupus erythematosus.
@en
IFNα and its response proteins ...... systemic lupus erythematosus.
@nl
P2093
P2860
P50
P1476
IFNα and its response proteins ...... systemic lupus erythematosus.
@en
P2093
Andreas Grützkau
Andreas Radbruch
Andrzej Dzionek
Cornelia Dähnrich
Dörte Huscher
Falk Hiepe
Heike Hirseland
Philipp Enghard
Robert Biesen
Thomas Rose
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-201586
P407
P50
P577
2012-10-31T00:00:00Z